Cargando…

Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes

This review addresses appropriate patient selection for upadacitinib, a Janus kinase inhibitor approved by the FDA and EMA for treatment of moderately to severely active ulcerative colitis (UC). Janus kinase molecules can contribute to the inflammatory pathway, so inhibiting certain of them may prov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Irani, Malcolm, Fan, Christopher, Glassner, Kerri, Abraham, Bincy P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10007976/ https://www.ncbi.nlm.nih.gov/pubmed/36915649 http://dx.doi.org/10.2147/CEG.S367086

Ejemplares similares

Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
por: Ernest-Suarez, Kenneth, et al.
Publicado: (2023)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
por: Napolitano, Maria, et al.
Publicado: (2022)

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
por: Grieco, Teresa, et al.
Publicado: (2023)

Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis
por: Ghosh, Subrata, et al.
Publicado: (2021)

Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
por: Ponce-Bobadilla, Ana Victoria, et al.
Publicado: (2022)

Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis
por: Yan, Brian M., et al.
Publicado: (2021)

Upadacitinib as a Rescue Therapy in Acute Severe Ulcerative Colitis: A Case Report and Review of the Literature
por: Ali, Nargess Mahmoud, et al.
Publicado: (2023)

Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results
por: Panés, Julian, et al.
Publicado: (2023)

A case of nocardiosis in a patient with ulcerative colitis on chronic corticosteroids, infliximab, and upadacitinib
por: Moy, Benjamin M., et al.
Publicado: (2023)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Using a Deep Learning Model to Address Interobserver Variability in the Evaluation of Ulcerative Colitis (UC) Severity
por: Kim, Jeong-Heon, et al.
Publicado: (2023)

Dose Escalation of Biologics in Biologic-Naïve Patients With Ulcerative Colitis: Outcomes From the ODESSA-UC Study
por: Ghosh, Sabyasachi, et al.
Publicado: (2023)

The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Anti-ulcerogenic and anti-ulcerative colitis (UC) activities of seven amines derivatives
por: Awaad, Amani S., et al.
Publicado: (2017)

Prevalence of Intestinal Protozoan Infection in Patients with Ulcerative Colitis (UC) in Isfahan, Iran
por: Pestechian, Nader, et al.
Publicado: (2021)

Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial
por: Sarbagili Shabat, Chen, et al.
Publicado: (2021)

Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician
por: Saleh, Adam, et al.
Publicado: (2022)

REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis: A Canadian IBD Research Consortium Multicenter National Cohort Study
por: Ma, Christopher, et al.
Publicado: (2023)

A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
por: Edwards, Christopher J., et al.
Publicado: (2020)

Infliximab-Induced Non-specific Interstitial Pneumonitis in a Patient With Ulcerative Colitis (UC)
por: Nasir, Syed Alishan, et al.
Publicado: (2022)

Development and validation of the Ulcerative Colitis patient-reported outcomes signs and symptoms (UC-pro/SS) diary
por: Higgins, Peter D. R., et al.
Publicado: (2018)

Medically Refractory Lymphocytic Colitis Successfully Treated With Upadacitinib
por: Miyatani, Yusuke, et al.
Publicado: (2023)

Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
por: Jentzer, Alexandre, et al.
Publicado: (2020)

Involvement of Proinflammatory Arachidonic Acid (ARA) Derivatives in Crohn’s Disease (CD) and Ulcerative Colitis (UC)
por: Kikut, Justyna, et al.
Publicado: (2022)

Potential Biomarkers Associated with Differential Manifestations of Ulcerative Colitis (UC) in Uyghur and Han Population in China
por: Lu, Jia Jie, et al.
Publicado: (2021)

A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study
por: Sarbagili-Shabat, Chen, et al.
Publicado: (2021)

DNA Methylation Status of Epithelial-Mesenchymal Transition (EMT) - Related Genes Is Associated with Severe Clinical Phenotypes in Ulcerative Colitis (UC)
por: Tahara, Tomomitsu, et al.
Publicado: (2014)

Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results
por: Hyams, Jeffrey S, et al.
Publicado: (2020)

Intestinal ultrasound for monitoring therapeutic response in patients with ulcerative colitis: results from the TRUST&UC study
por: Maaser, Christian, et al.
Publicado: (2020)

Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index
por: Bots, Steven, et al.
Publicado: (2021)

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Blauvelt, Andrew, et al.
Publicado: (2021)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Energy Expenditure in Japanese Patients with Severe or Moderate Ulcerative Colitis
por: Sasaki, Masaya, et al.
Publicado: (2010)

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
por: Freeman, Hugh J
Publicado: (2013)

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Evaluation of diet pattern related to the symptoms of mexican patients with Ulcerative Colitis (UC): through the validity of a questionnaire
por: Bueno-Hernández, Nallely, et al.
Publicado: (2015)

Ecological and network analyses identify four microbial species with potential significance for the diagnosis/treatment of ulcerative colitis (UC)
por: Li, Wendy, et al.
Publicado: (2021)

Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
por: Conaghan, Philip, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ev0h0icijdll6raha1s109fu7g